Microbial preparation of 13.beta.-13-deoxy-22,23-dihydro avermectin-B1A/B1B aglycone
AssigneeMerck & Co., Inc.
InventorsKalinka Shumanov, Raymond F. White
Life of this patent
Estimating the term…
Abstract
The known compound, 13.beta.-13-deoxy-22,23-dihydro-avermectin -B1a/B1b Aglycone is prepared microbiologically from cultures of the novel microorganisms (MA-6762, ATCC 55069, MA-6763 ATCC 55070) or the known microorganism Streptomyces lavendulae MA-6555 (ATCC 14159 or ATCC 55330). The compound is prepared by the biotransformation of 13-deoxy-22,23-dihydro avermectin B1a/B1b aglycone which oxidizes the 13-position and epimerizes the 13-position hydroxy group.
Claims12
A process for the preparation of 13-.beta.-22,23-dihydro avermectin B1a/B1b aglycone which comprises fermenting in an aqueous nutrient medium with assimilable sources of carbon, nitrogen and inorganic salts, a culture of Streptomyces griseus MA-6762, MA-6763-selected from the group consisting of Streptomyces griseus MA-6762 ATCC 55069, Streptomyces griseus MA-6763 ATCC 55070, Streptomyces lavendulae MA-6555 ATCC 14159 and Streptomyces lavendulae MA-6555 ATCC 55330 and the added compound 13-deoxy-22,23-dihydro avermectin B1a/B1b aglycone in about 0.05 mg per milliliter of the fermentation medium and recovering 13-.beta.-22,23-dihydro avermectin Bla/Blb aglycone and the added compound 13-deoxy-22,23-dihydro avermectin B1a/B1b and recovering the desired compound.
Dependencies are inferred from the claim text.